Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Economia

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

SEQENS Is Unveiling Its Main Innovation and Development Centre

Business Wire

A 34,000-square-metre science platform, SEQENS'Lab offers a unique ecosystem, dedicated to our customers to accelerate their projects from the early research and development stages to commercial scale production. Close to Paris, SEQENS'Lab is the centre of excellence for developing a totally unique package of R&D services.

SEQENS'Lab is a development accelerator, dedicated to our customers

As an R&D centre that meets the highest standards, SEQENS’Lab has assembled the group’s key skills and expertise in recognised areas of excellence such as: organic chemistry development at the forefront of the latest innovations, two referring laboratories in Physics & Solid-State Chemistry as well as in Process Safety, kinetic and thermodynamic simulation tools, large batch manufacturing capabilities for preclinical and clinical studies, all in an environment that adheres to cGMP.

Furthermore, it has innovative means for developing future processes, particularly in flow chemistry, that are more productive and energy-efficient and have minimal environmental impact.

Innovative SMEs and start-ups that are specialised in analytical services and CROs will be hosted at SEQENS’Lab, giving our customers access to complementary skills in one place. The example of GenEvolution demonstrates this: partner from the very beginning, it brings key skills to SEQENS’Lab in toxicology for medicine, chemical ingredients, plant extracts and cosmetic ingredient evaluation thanks to the miniaturization of its in-vitro tests.

SEQENS'Lab is an appealing and modern place, it reflects the group's development dynamic

“The SEQENS’ Lab will also welcome external resources, innovative start-ups and our historic partners, forming a dynamic and cohesive ecosystem in service of innovation. We also want to facilitate interactions with our academic partners and create a LabCom with CNRS (French National Centre for Scientific Research) to design and develop highly innovative solutions,” added Christophe Eychenne-Baron, R&D director.

About SEQENS

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients.

With 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia, SEQENS develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

www.seqens.com

Aline Rancony
Aline.rancony@seqens.com
(+33) 6 79 18 53 92

Permalink: http://www.businesswire.com/news/home/20190617005912/en

Video Economia


Vai al sito: Who's Who

Modifica consenso Cookie